# Selected publications (display-ready authors)
- title: "Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling"
  authors_display: "Alig et al."
  venue: Nature
  year: 2024
  url: https://doi.org/10.1038/s41586-023-06903-x

- title: "Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas"
  authors_display: "Sworder*, Kurtz*, Alig*, Frank* et al."
  venue: Cancer Cell
  year: 2023
  url: https://doi.org/10.1016/j.ccell.2022.12.005

- title: "Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas"
  authors_display: "Mutter*, Alig* et al."
  venue: Journal of Clinical Oncology
  year: 2023
  url: https://doi.org/10.1200/JCO.22.00826

- title: "A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL"
  authors_display: "Cherng*, Alig* et al."
  venue: Blood Advances
  year: 2023
  url: https://doi.org/10.1182/bloodadvances.2022008174

- title: "Inferring gene expression from cell‑free DNA fragmentation profiles"
  authors_display: "Esfahani et al."
  venue: Nature Biotechnology
  year: 2022
  url: https://doi.org/10.1038/s41587-022-01222-4

- title: "Short Diagnosis‑to‑Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B‑Cell Lymphoma"
  authors_display: "Alig et al."
  venue: Journal of Clinical Oncology
  year: 2021
  url: https://doi.org/10.1200/JCO.20.02573

- title: "Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA"
  authors_display: "Kurtz et al."
  venue: Nature Biotechnology
  year: 2021
  url: https://doi.org/10.1038/s41587-021-00981-w
- title: "Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma"
  authors_display: "Mark Roschewski*, Alig* et al."
  venue: Journal of Clinical Oncology
  year: 2025 
  url: https://doi.org/10.1200/JCO-25-01534

